BriaCell Therapeutics (BCTX) Competitors $4.48 +0.73 (+19.47%) As of 04/16/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCTX vs. SAVA, VTGN, JSPR, IVVD, VHAQ, INZY, ALTS, CLSD, VTVT, and BMEAShould you be buying BriaCell Therapeutics stock or one of its competitors? The main competitors of BriaCell Therapeutics include Cassava Sciences (SAVA), Vistagen Therapeutics (VTGN), Jasper Therapeutics (JSPR), Invivyd (IVVD), Viveon Health Acquisition (VHAQ), Inozyme Pharma (INZY), Janone (ALTS), Clearside Biomedical (CLSD), vTv Therapeutics (VTVT), and Biomea Fusion (BMEA). These companies are all part of the "pharmaceutical products" industry. BriaCell Therapeutics vs. Cassava Sciences Vistagen Therapeutics Jasper Therapeutics Invivyd Viveon Health Acquisition Inozyme Pharma Janone Clearside Biomedical vTv Therapeutics Biomea Fusion Cassava Sciences (NASDAQ:SAVA) and BriaCell Therapeutics (NASDAQ:BCTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership. Do institutionals & insiders hold more shares of SAVA or BCTX? 38.0% of Cassava Sciences shares are held by institutional investors. Comparatively, 15.4% of BriaCell Therapeutics shares are held by institutional investors. 9.0% of Cassava Sciences shares are held by company insiders. Comparatively, 5.7% of BriaCell Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media favor SAVA or BCTX? In the previous week, BriaCell Therapeutics had 1 more articles in the media than Cassava Sciences. MarketBeat recorded 1 mentions for BriaCell Therapeutics and 0 mentions for Cassava Sciences. BriaCell Therapeutics' average media sentiment score of 0.94 beat Cassava Sciences' score of 0.74 indicating that BriaCell Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Cassava Sciences Positive BriaCell Therapeutics Positive Which has more risk & volatility, SAVA or BCTX? Cassava Sciences has a beta of -1.48, meaning that its share price is 248% less volatile than the S&P 500. Comparatively, BriaCell Therapeutics has a beta of 1.34, meaning that its share price is 34% more volatile than the S&P 500. Is SAVA or BCTX more profitable? BriaCell Therapeutics' return on equity of 0.00% beat Cassava Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Cassava SciencesN/A -88.05% -64.98% BriaCell Therapeutics N/A N/A -191.19% Does the MarketBeat Community prefer SAVA or BCTX? Cassava Sciences received 86 more outperform votes than BriaCell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave BriaCell Therapeutics an outperform vote while only 64.47% of users gave Cassava Sciences an outperform vote. CompanyUnderperformOutperformCassava SciencesOutperform Votes9864.47% Underperform Votes5435.53% BriaCell TherapeuticsOutperform Votes12100.00% Underperform VotesNo Votes Do analysts recommend SAVA or BCTX? Cassava Sciences presently has a consensus target price of $54.50, indicating a potential upside of 3,792.86%. BriaCell Therapeutics has a consensus target price of $32.00, indicating a potential upside of 614.29%. Given Cassava Sciences' higher probable upside, equities research analysts clearly believe Cassava Sciences is more favorable than BriaCell Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cassava Sciences 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50BriaCell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has stronger valuation & earnings, SAVA or BCTX? Cassava Sciences is trading at a lower price-to-earnings ratio than BriaCell Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCassava SciencesN/AN/A-$97.22M-$1.45-0.97BriaCell TherapeuticsN/AN/A-$4.79M-$5.03-0.89 SummaryBriaCell Therapeutics beats Cassava Sciences on 8 of the 14 factors compared between the two stocks. Remove Ads Get BriaCell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BCTX vs. The Competition Export to ExcelMetricBriaCell TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.62M$6.26B$5.28B$7.35BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-0.346.6921.6517.68Price / SalesN/A222.70371.0992.89Price / CashN/A65.6738.1534.64Price / Book-2.045.776.373.94Net Income-$4.79M$142.01M$3.20B$247.45M7 Day Performance11.72%5.79%3.76%3.17%1 Month Performance10.07%-15.47%-10.49%-8.53%1 Year Performance-86.17%-10.99%10.39%0.32% BriaCell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BCTXBriaCell Therapeutics1.69 of 5 stars$4.48+19.5%$32.00+614.3%-86.7%$16.62MN/A-0.348News CoverageGap UpHigh Trading VolumeSAVACassava Sciences3.8146 of 5 stars$1.34+5.5%$54.50+3,967.2%-93.3%$64.73MN/A-0.9730VTGNVistagen Therapeutics1.9465 of 5 stars$2.23+5.2%N/A-55.5%$64.36M$698,000.00-1.5140Gap DownJSPRJasper Therapeutics1.9545 of 5 stars$4.20+1.0%$62.50+1,388.1%-83.8%$63.09MN/A-0.8920IVVDInvivyd2.5421 of 5 stars$0.53-4.4%$7.52+1,331.5%-82.5%$62.99M$25.38M-0.27100Short Interest ↑Gap DownVHAQViveon Health AcquisitionN/A$11.00flatN/AN/A$62.26MN/A0.002High Trading VolumeINZYInozyme Pharma2.8355 of 5 stars$0.97+9.4%$14.63+1,409.1%-80.2%$62.26MN/A-0.6250News CoverageALTSJanoneN/A$3.85flatN/AN/A$61.90M$12.53M0.00170Short Interest ↑CLSDClearside Biomedical2.8745 of 5 stars$0.80+4.6%$5.25+556.2%-24.4%$61.83M$1.66M-1.7830Short Interest ↓VTVTvTv Therapeutics2.2308 of 5 stars$19.36+3.1%$35.50+83.4%-22.0%$61.76M$1.02M-4.279Analyst ForecastShort Interest ↓BMEABiomea Fusion2.6669 of 5 stars$1.62-7.4%$23.91+1,375.9%-86.7%$60.87MN/A-0.4050Positive News Remove Ads Related Companies and Tools Related Companies SAVA Alternatives VTGN Alternatives JSPR Alternatives IVVD Alternatives VHAQ Alternatives INZY Alternatives ALTS Alternatives CLSD Alternatives VTVT Alternatives BMEA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BCTX) was last updated on 4/17/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsElon Musk just confirmed Tesla’s robot will go to Mars. But on Earth, it may trigger a trillion-dollar tech sh...InvestorPlace | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredAmazon ShockerJeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BriaCell Therapeutics Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share BriaCell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
